Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab.

This case report describes a patient with hepatitis C virus infection responding to pegylated INF/ribaviron therapy, who developed immune thrombocytopenia. The severe thrombocytopenia failed to resolve with cessation of the peg-IFN/ribaviron. Because of rising hepatitis C virus RNA levels and evidence of rising serum transaminases, the patient was treated with rituximab, anti-CD20 humanized monoclonal antibody. After treatment with rituximab, the patient's platelet count normalized and the patient was able to resume the pegylated IFN/ribaviron. The patient's hepatitis C virus RNA levels decreased, and the serum transaminases normalized without impairment of hepatic function or recurrence of the thrombocytopenia. Copyright 2005 Wiley-Liss, Inc.